Skip to main content
. Author manuscript; available in PMC: 2013 Aug 24.
Published in final edited form as: Immunity. 2012 Aug 9;37(2):249–263. doi: 10.1016/j.immuni.2012.05.023

Figure 7. Gal1 Therapy Ameliorates EAE, Limits Microglia Activation, Controls Axonal Loss and Promotes Synaptic Repair.

Figure 7

(A) Disease score (left) of vehicle-treated and Gal1-treated (100 μg/ day) mice, immunized with 200 μg MOG35-55 and linear regression curves of disease for each group (right, dashed lines, 95% confidence intervals). (B) Bielschowsky silver (upper panel) and Luxol fast blue (lower panel) staining of spinal cord after 35 days of EAE in Gal1- or vehicle-treated mice. (C-G) Confocal microscopy of spinal cord white matter on day 35 post-immunization in Gal1- or vehicle-treated mice. (C) Left, sections were stained for Iba1 (green) and MHC II (red). Insert shows low magnification micrograph of representative cells. Middle. 3D reconstruction ortho-view of low magnification micrograph. Right, graph represents a quantification of Iba1, MHCII double positive cells in different groups. (D) Left, spinal cord sections were stained for Tuj1 (green). Middle, 2.5D intensity analysis of Tuj1 staining Right, mean fluorescence intensity (MFI) of immunoreactivity against Tuj1. (E) Left, spinal cord sections were stained for GAP43 (green). Middle, 2.5D intensity analysis of GAP43 staining Right, mean fluorescence intensity (MFI) of immunoreactivity against GAP43. (F) Left, spinal cord sections were stained for MBP (green). Middle. 2.5D intensity analysis of MBP staining. Right, mean fluorescence intensity (MFI) of immunoreactivity against MBP. (G) Left, Spinal cord sections were stained for GFAP (green). Middle, 2.5D intensity analysis of GFAP staining. Right, mean fluorescence intensity (MFI) of immunoreactivity against GFAP. (H,I) Neonatal microglia were pre-treated in vitro with vehicle, LPS, Gal1 or LPS plus Gal1 for 24 h before transfer to the right lateral ventricle of Lgals1−/− EAE mice (day 9 post-immunization; n=6 per group). (H) Diagram illustrating the injection site. (I) Clinical score (left) and linear regression curves of disease for each group (right; dashed lines; 95% confidence intervals). Scale bars = 20 μm. Data are the mean ± SEM (A, C-G, I) or are representative (B-G, images) of four independent experiments. *P<0.05; **P<0.01; ***P<0.005 versus vehicle. See also Figure S7.